50 related articles for article (PubMed ID: 22728551)
1. [Critical role of activating immune receptor DNAM-1 in the development of acute GVHD].
Kanaya M; Nabekura T; Shibuya K; Shibuya A
Rinsho Ketsueki; 2012 May; 53(5):497-503. PubMed ID: 22728551
[No Abstract] [Full Text] [Related]
2. Establishment and characterization of a novel anti-DNAM-1 monoclonal antibody.
Yamashita Y; Abe F; Hirochika R; Tahara-Hanaoka S; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):60-4. PubMed ID: 23600509
[TBL] [Abstract][Full Text] [Related]
3. Effector cells of lethal graft-versus-host disease (GVHD) in nude mice.
Uenaka A; Mieno M; Kuribayashi K; Shiku H; Nakayama E
Transplant Proc; 1989 Feb; 21(1 Pt 3):3031-2. PubMed ID: 2784924
[No Abstract] [Full Text] [Related]
4. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.
Okumura G; Abe F; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):135-139. PubMed ID: 28498033
[TBL] [Abstract][Full Text] [Related]
6. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
7. Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD.
Fujimura J; Takeda K; Kaduka Y; Saito M; Akiba H; Yagita H; Yamashiro Y; Shimizu T; Okumura K
Pediatr Transplant; 2010 Jun; 14(4):540-8. PubMed ID: 20136724
[TBL] [Abstract][Full Text] [Related]
8. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
[TBL] [Abstract][Full Text] [Related]
9. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones.
Parkman R
J Immunol; 1986 May; 136(10):3543-8. PubMed ID: 2871104
[TBL] [Abstract][Full Text] [Related]
10. Short-term homing assay reveals a critical role for lymphocyte function-associated antigen-1 in the hepatic recruitment of lymphocytes in graft-versus-host disease.
Sato T; Habtezion A; Beilhack A; Schulz S; Butcher E; Thorlacius H
J Hepatol; 2006 Jun; 44(6):1132-40. PubMed ID: 16466827
[TBL] [Abstract][Full Text] [Related]
11. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
12. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
13. Locally administered monoclonal antibodies to lymphocyte function-associated antigen 1 and to L3T4 prevent cutaneous graft-vs-host disease.
Shiohara T; Moriya N; Gotoh C; Saizawa K; Nagashima M
J Immunol; 1988 Oct; 141(7):2261-7. PubMed ID: 3049803
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
16. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
Friedman TM; Gilbert M; Briggs C; Korngold R
J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
[TBL] [Abstract][Full Text] [Related]
17. Expression level of costimulatory receptor ICOS is critical for determining the polarization of helper T cell function.
Watanabe S; Ogawa S; Hara Y; Tanabe K; Toma H; Abe R
Transpl Immunol; 2006 Apr; 15(4):255-63. PubMed ID: 16635747
[TBL] [Abstract][Full Text] [Related]
18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.
Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ
J Immunol; 1999 Apr; 162(8):4373-6. PubMed ID: 10201970
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease.
Williamson E; Garside P; Bradley JA; More IA; Mowat AM
J Immunol; 1997 Aug; 159(3):1208-15. PubMed ID: 9233615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
